Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][2]. Core Insights - The report maintains a positive outlook on the pharmaceutical industry, indicating that it expects the overall returns to exceed the CSI 300 Index by more than 5% over the next six months [7]. - Recent market performance shows the pharmaceutical sector increased by 0.19% on July 9, 2024, underperforming the CSI 300 Index by 1.00 percentage points, ranking 28th among 31 sub-industries [5]. - Notable stock performances include Guoyao Modern (+9.96%), Ganli Pharmaceutical (+6.87%), and Yingke Medical (+6.21%) leading the gains, while Rongchang Bio (-19.99%), Puli Pharmaceutical (-19.64%), and Tai'an Retreat (-10.00%) faced significant declines [5]. Summary by Sections Market Performance - As of July 9, 2024, the pharmaceutical sector's performance was +0.19%, lagging behind the CSI 300 Index by 1.00 percentage points, with blood products (+1.55%) and medical consumables (+0.64%) performing well, while offline pharmacies (-2.11%) and hospitals (-0.01%) lagged [5]. Industry News - Eli Lilly announced a $3.2 billion acquisition of Morphic, gaining access to its oral integrin therapy MORF-057, aimed at treating inflammatory bowel disease (IBD) [6]. - Noteworthy company announcements include: - Aorite expects a net profit of 175-215 million yuan for the first half of 2024, a year-on-year increase of 82%-124% [6]. - Shutaishen received approval for clinical trials of STSP-0902 eye drops for treating neurotrophic keratitis [6]. - Renfu Pharmaceutical's subsidiary received a drug registration certificate for esketamine injection [6]. - Haooubo received approval for clinical trials of MM09 sublingual spray for treating moderate to severe allergic rhinitis [6].
医药行业周报：礼来以32美元收购Morphic，囊获IBD相关管线
Tai Ping Yang·2024-07-11 05:00